PRESS RELEASES

Thursday, February 4, 2010
OXiGENE Announces Results of Stockholder Vote on Proposed Merger With VaxGen

Monday, December 7, 2009
OXiGENE Reports Promising Preclinical Data Using OXi4503 in Acute Myelogenous Leukemia Models at ASH Conference

CONFERENCE POSTERS

2009 AACR-NCI-EORTC Conference FALCON Interim Data
Interim Safety Results of a Randomized Ph 2 Trial of a Tumor Vascular Disrupting Agent Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC)
November 2009

D. Patterson et al.
OXi4503 Interim Phase I Results
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 2007

P. Nathan et al.
ZYBRESTAT™ + Bevacizumab Phase Ib Interim Results
European School of Haematology's International Conference on Vascular Targeted Therapies in Oncology, Mandelieu, France, October 2007

NEWS ARTICLES

Young S, Chaplin D. September 2004
Combretastatin A4 phosphate: background and current clinical status.
Expert Opin. Investig. Drugs. 13(9):1171-82

Siemann D, Chaplin D, Horsman MR. June 15, 2004
Vascular-Targeting Therapies for Treatment of Malignant Disease.
Cancer. 100(12):2491-9

PUBLICATIONS

Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ. February 15, 2005
Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin.
Clinical Cancer Research 11:1527-33

Dowlatti A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC. June 15, 2002
A Phase I Pharmacokinetic and Translational Study of the novel Vascular Targeting Agent CA4P on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer.
Cancer Research 62(12):3408-16